Clinical Trial

Sirolimus Discontinuation Strategies in Kaposiform Hemangioendothelioma

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Sirolimus has demonstrated efficacy in the treatment of kaposiform hemangioendothelioma (KHE); however, a high rate of rebound growth following discontinuation has been reported, highlighting the clinical importance of establishing an appropriate withdrawal regimen.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-08-13.
Trial Details
NCT Number NCT07131644
Lead Sponsor West China Hospital
Conditions Kaposiform Hemangioendothelioma
Enrollment 120 participants
Start Date 2025-09-13
Primary Completion 2027-09-01 (estimated)
Study Completion 2028-02-01 (estimated)
Updated on ClinicalTrials.gov 2025-09-08